MCID: ADN009
MIFTS: 53

Adenosquamous Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 15 73
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 44
Carcinoma Adenosquamous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 44 D018196
NCIt 50 C3727
SNOMED-CT 68 403902008 59367005
UMLS 73 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to adenosquamous pancreas carcinoma and syringocystadenoma papilliferum. An important gene associated with Adenosquamous Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Development EGFR signaling pathway and MicroRNAs in cancer. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and pancreas, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 adenosquamous pancreas carcinoma 31.7 KRAS KRT5 KRT7 PTHLH
2 syringocystadenoma papilliferum 30.7 KRAS MUC1
3 ampulla of vater neoplasm 30.7 KRAS KRT7 MUC1
4 cervical adenocarcinoma 30.6 EGFR KRT7 TP53
5 hidradenoma 30.4 KRT7 MUC1
6 adenocarcinoma 30.3 EGFR KRAS MUC1 MUC4 TP53
7 cystadenoma 30.2 KRT7 MUC1 MUC4
8 dermoid cyst 30.2 KRT7 MUC1 TP63
9 intestinal perforation 30.2 KRT7 NKX2-1
10 villous adenoma 30.2 KRAS MUC1
11 large cell neuroendocrine carcinoma 30.0 EGFR KRT7 NKX2-1
12 cystic teratoma 29.9 KRT7 NKX2-1 TP53
13 cystadenocarcinoma 29.9 KRT7 MUC1 TP53
14 teratoma 29.9 KRT7 NKX2-1 TP53
15 gastrointestinal stromal tumor 29.7 EGFR KRAS TP53
16 mucoepidermoid carcinoma 29.5 EGFR KRT7 MUC1 MUC4 TP63
17 cholecystitis 29.3 KRT18 MUC1 TP53
18 necrotizing sialometaplasia 29.3 KRT5 KRT7 TP53 TP63
19 small cell carcinoma 29.2 EGFR KRT7 NKX2-1 TP53
20 small cell cancer of the lung 29.1 EGFR KRT7 NKX2-1 TP53
21 endometrial cancer 28.7 AR EGFR KRAS KRT7 TP53
22 lymphoepithelioma-like carcinoma 28.7 KRT18 KRT5 KRT7 KRT8 MUC1
23 papilloma 28.7 KRT5 KRT7 KRT8 TP53 TP63
24 squamous cell carcinoma 28.4 EGFR KRAS MUC1 PTHLH TP53 TP63
25 lung squamous cell carcinoma 27.9 EGFR KRAS PTHLH TP53 TP63
26 large cell carcinoma 27.4 EGFR KRT5 KRT7 NKX2-1 PTHLH TP63
27 lung cancer 25.2 EGFR KRAS KRT18 KRT7 MUC4 NKX2-1
28 glassy cell variant cervical adenosquamous carcinoma 12.3
29 endometrial adenosquamous carcinoma 12.2
30 gastric adenosquamous carcinoma 12.2
31 cervical adenosquamous carcinoma 12.2
32 esophageal adenosquamous carcinoma 12.2
33 thymus adenosquamous carcinoma 12.2
34 bartholin's gland adenosquamous carcinoma 12.0
35 ampulla of vater adenosquamous carcinoma 12.0
36 adenosquamous cell lung carcinoma 11.5
37 adenosquamous colon carcinoma 11.5
38 adenosquamous prostate carcinoma 11.5
39 adenosquamous gallbladder carcinoma 11.5
40 adenosquamous bile duct carcinoma 11.0
41 paronychia 10.9 EGFR KRAS
42 breast scirrhous carcinoma 10.9 EGFR MUC1
43 malignant peritoneal mesothelioma 10.8 EGFR MUC1
44 apocrine adenoma 10.8 KRAS MUC1
45 inverted transitional papilloma 10.8 KRT5 KRT7
46 endosalpingiosis 10.8 KRT7 MUC1
47 balloon cell malignant melanoma 10.8 KRT5 KRT7
48 sensory organ benign neoplasm 10.8 KRT5 KRT7
49 parachordoma 10.8 KRT7 MUC1
50 endolymphatic sac tumor 10.8 KRT7 KRT8

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.91 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-154 9.91 KRT18
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.91 KRT18 KRT5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.91 KRT8 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.91 KRT5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.91 KRT18
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.91 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.91 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.91 KRT7 KRT8 KRT18 KRT5
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.91 KRT7
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.91 KRT18
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.91 KRT7 KRT5
13 Decreased viability GR00055-A-2 9.44 EGFR MUC1 KRAS
14 Decreased viability GR00106-A-0 9.44 KRAS
15 Decreased viability GR00221-A-1 9.44 EGFR KRAS
16 Decreased viability GR00221-A-2 9.44 KRAS
17 Decreased viability GR00221-A-4 9.44 EGFR
18 Decreased viability GR00301-A 9.44 KRAS
19 Decreased viability GR00381-A-1 9.44 KRAS
20 Decreased viability GR00402-S-2 9.44 EGFR MUC1 KRAS

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.19 KRT8 TP53 NKX2-1 TP63 PTHLH AR
2 growth/size/body region MP:0005378 10.19 KRT8 TP53 NKX2-1 TP63 PTHLH KRT5
3 cardiovascular system MP:0005385 10.16 KRT8 TP53 NKX2-1 PTHLH TP63 AR
4 mortality/aging MP:0010768 10.1 KRT8 TP53 NKX2-1 PTHLH EGFR KRT5
5 craniofacial MP:0005382 10.09 TP53 TP63 PTHLH KRT5 AR KRAS
6 embryo MP:0005380 10.07 KRT8 TP53 TP63 AR KRAS KRT18
7 endocrine/exocrine gland MP:0005379 10.05 PTHLH TP53 NKX2-1 EGFR AR KRAS
8 integument MP:0010771 10.02 TP53 PTHLH EGFR KRT5 AR KRAS
9 limbs/digits/tail MP:0005371 10 TP53 TP63 PTHLH KRT5 AR KRAS
10 liver/biliary system MP:0005370 9.91 KRT8 TP53 EGFR AR KRAS KRT18
11 neoplasm MP:0002006 9.85 TP53 NKX2-1 TP63 AR KRAS EGFR
12 no phenotypic analysis MP:0003012 9.8 TP53 NKX2-1 KRT5 EGFR KRAS TP63
13 renal/urinary system MP:0005367 9.8 KRT7 TP53 TP63 PTHLH AR KRAS
14 reproductive system MP:0005389 9.76 KRT8 TP53 NKX2-1 TP63 PTHLH AR
15 respiratory system MP:0005388 9.43 TP53 NKX2-1 PTHLH EGFR KRAS TP63
16 skeleton MP:0005390 9.17 PTHLH TP53 NKX2-1 EGFR AR KRAS

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
9
Vinblastine Approved Phase 3 865-21-4 13342 241903
10
Ifosfamide Approved Phase 3 3778-73-2 3690
11
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
14
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
15
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
16
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
17
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
18
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
20
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
21
Doxil Approved June 1999 Phase 3,Phase 1 31703
22 insulin Phase 3
23 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
24 Antibodies Phase 3,Phase 2,Phase 1
25 Immunoglobulins Phase 3,Phase 2,Phase 1
26 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
27 Insulin, Globin Zinc Phase 3
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
30
Isophosphamide mustard Phase 3 0
31 Alkylating Agents Phase 3,Phase 2,Phase 1
32 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
33 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
34 Folic Acid Antagonists Phase 3,Phase 2
35 Mitogens Phase 3,Phase 2,Phase 1
36 Mitomycins Phase 3
37 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
38 Dermatologic Agents Phase 3
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
40 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
41 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
42 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Vitamin B Complex Phase 3,Phase 2
45 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
46 Immunoglobulin G Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 1,Phase 2
50 Antimetabolites Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
6 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
8 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
13 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
14 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
15 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
17 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
18 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
19 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
20 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
21 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
22 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
23 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
24 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
25 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
26 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
27 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
28 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
29 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
30 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
31 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
32 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
34 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
36 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
37 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
38 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
39 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
40 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
41 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
42 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
43 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
44 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
45 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
46 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
47 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
48 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
49 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
50 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

41
Cervix, Lung, Pancreas, Lymph Node, Breast, Colon, Liver

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 543)
# Title Authors Year
1
Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. ( 29878370 )
2018
2
A retroperitoneal mass confirmed as a pancreatic adenosquamous carcinoma by endoscopic ultrasound-guided fine-needle aspiration. ( 29069702 )
2018
3
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. ( 29609906 )
2018
4
A Rare Case of Penile Metastases as a Harbinger of Primary Pulmonary Adenosquamous Carcinoma. ( 29785317 )
2018
5
High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. ( 29537649 )
2018
6
Clinicopathological characteristics and survival outcomes in adenosquamous carcinoma of the lung: a population-based study from the SEER database. ( 29487721 )
2018
7
Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutes. ( 29850145 )
2018
8
Adenosquamous Carcinoma in the Midline Dorsum of the Tongue: A Rare Case Report. ( 29806990 )
2018
9
Pancreatic adenosquamous carcinoma masquerading as a locally invading splenic abscess. ( 29740918 )
2018
10
Long-term survival with extended lateral lymphadenectomy for lateral lymph node recurrence after laparoscopic abdominoperineal resection for rectal adenosquamous carcinoma: a case report. ( 29633041 )
2018
11
Adenosquamous carcinoma of the bile duct: a population-based study. ( 29563834 )
2018
12
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. ( 28848104 )
2017
13
Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy. ( 28493097 )
2017
14
Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. ( 28098663 )
2017
15
Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. ( 28123305 )
2017
16
Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. ( 29258074 )
2017
17
Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report. ( 29145336 )
2017
18
CD117 expression in adenosquamous carcinoma. ( 28766737 )
2017
19
Genomic signatures of pancreatic adenosquamous carcinoma (PASC). ( 28722109 )
2017
20
Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. ( 28784574 )
2017
21
Pancreatic adenosquamous carcinoma and intraductal papillary mucinous neoplasm in a<i>CDKN2A</i>germline mutation carrier. ( 28979722 )
2017
22
Importance of tumor extent in adenosquamous carcinoma of the head and neck: a retrospective cohort study. ( 28412233 )
2017
23
Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report. ( 28357109 )
2017
24
Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. ( 28816351 )
2017
25
Clinicopathological features and prognosis of gastric adenosquamous carcinoma. ( 28676632 )
2017
26
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 28465645 )
2017
27
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. ( 28387300 )
2017
28
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
29
The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma. ( 28397462 )
2017
30
Spontaneous pulmonary adenosquamous carcinoma in a free-living black capuchin monkey (Sapajus nigritus). ( 29283438 )
2017
31
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. ( 29203990 )
2017
32
Adenosquamous Carcinoma of the Colon. ( 29606937 )
2017
33
A case of melanocytic cervical adenosquamous carcinoma complicated with Cushing's syndrome. ( 29767880 )
2017
34
Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma. ( 29085501 )
2017
35
Adenosquamous Carcinoma of the Tongue. ( 29243024 )
2017
36
Characterization of primary pulmonary adenosquamous carcinoma-associated pleural effusion. ( 26797868 )
2016
37
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. ( 27514842 )
2016
38
Primary Colon Adenosquamous Carcinoma in a Patient With Lynch Syndrome: A New Histologic Subtype Associated With Microsatellite Instability? ( 27422471 )
2016
39
Pulmonary micropapillary-type adenosquamous carcinoma sharing epidermal growth factor receptor mutation in adenocarcinoma and squamous cell carcinoma. ( 28127432 )
2016
40
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. ( 27918216 )
2016
41
A Case of Pancreatic Adenosquamous Carcinoma Obstructing the Common Bile and Pancreatic Ducts, Duodenum, and Gastric Outlet. ( 26863381 )
2016
42
Adenosquamous carcinoma of the tongue: clinicopathologic study and review of the literature. ( 27456683 )
2016
43
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
44
Primary cutaneous adenosquamous carcinoma of the penis: the first characterization of HPV status in this rare and diagnostically challenging entity with review of glandular carcinomas of the penis. ( 27696488 )
2016
45
Adenosquamous Carcinoma of the Duodenum: a Rare Entity. ( 27872539 )
2016
46
Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. ( 28034323 )
2016
47
Improved survival associated with a balanced structure between adenomatous and squamous components in patients with adenosquamous carcinoma of the lung. ( 27365198 )
2016
48
The Squamous Cells of Adenosquamous Carcinoma (ASCC) of the Prostate Might Represent a Terminally Differentiated Quiescent Component: Immunohistochemical Evidence From a Case of ASCC With Pleomorphic Giant Tumor Cells. ( 27753662 )
2016
49
Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience. ( 27002010 )
2016
50
MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 27748889 )
2016

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.46 AR MUC1 TP53 TP63
2 intermediate filament GO:0005882 9.26 KRT18 KRT5 KRT7 KRT8
3 keratin filament GO:0045095 8.92 KRT18 KRT5 KRT7 KRT8
4 cytoplasm GO:0005737 10.06 AR EGFR KRAS KRT18 KRT5 KRT7
5 nucleus GO:0005634 10 AR EGFR KRT18 KRT5 KRT7 KRT8

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.86 KRT18 KRT7 KRT8 TP53
2 positive regulation of gene expression GO:0010628 9.85 AR KRAS NKX2-1 TP53
3 cell proliferation GO:0008283 9.84 AR EGFR TP53 TP63
4 positive regulation of transcription, DNA-templated GO:0045893 9.77 AR EGFR NKX2-1 TP53 TP63
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.7 KRAS MUC1 MUC4
6 keratinization GO:0031424 9.62 KRT18 KRT5 KRT7 KRT8
7 anatomical structure formation involved in morphogenesis GO:0048646 9.58 NKX2-1 TP63
8 response to X-ray GO:0010165 9.57 TP53 TP63
9 prostate gland development GO:0030850 9.51 AR TP63
10 epithelial tube branching involved in lung morphogenesis GO:0060441 9.49 KRAS NKX2-1
11 cerebral cortex cell migration GO:0021795 9.48 EGFR NKX2-1
12 hepatocyte apoptotic process GO:0097284 9.46 KRT18 KRT8
13 cornification GO:0070268 9.46 KRT18 KRT5 KRT7 KRT8
14 Leydig cell differentiation GO:0033327 9.43 AR NKX2-1
15 mitotic G1 DNA damage checkpoint GO:0031571 9.4 TP53 TP63
16 morphogenesis of an epithelial fold GO:0060571 9.26 AR EGFR
17 epidermis development GO:0008544 9.26 EGFR KRT5 PTHLH TP63
18 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 MUC1 TP53 TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.62 AR EGFR TP53 TP63
2 enzyme binding GO:0019899 9.56 AR EGFR NKX2-1 TP53
3 transcription regulatory region DNA binding GO:0044212 9.46 AR NKX2-1 TP53 TP63
4 p53 binding GO:0002039 9.13 MUC1 TP53 TP63
5 scaffold protein binding GO:0097110 8.8 KRT18 KRT5 KRT8

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....